Kura Oncology (KURA) Shares Outstanding (Diluted Average) (2020 - 2026)

Kura Oncology (KURA) has 7 years of Shares Outstanding (Diluted Average) data on file, last reported at $88.6 million in Q1 2026.

• Shares Outstanding (Diluted Average) for Q1 2026 came in at $88.6 million, up 1.37% year-over-year; the trailing twelve-month figure through Mar 2026 was $88.6 million (up 1.37% YoY), and the FY2025 annual result was $87.7 million, up 1.76% from the prior year.
• Shares Outstanding (Diluted Average) grew to $88.6 million in Q1 2026 per KURA's latest filing, from $87.7 million in the prior quarter.
• Over five years, Shares Outstanding (Diluted Average) peaked at $88.6 million in Q1 2026 and troughed at $66.6 million in Q1 2022.
• A 5-year average of $78.7 million and a median of $83.9 million in 2024 frame the typical range for Shares Outstanding (Diluted Average).
• The sharpest annual moves came in 2022 and 2024: Shares Outstanding (Diluted Average) climbed 0.59% in 2022, then grew 24.13% in 2024.
• A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $67.0 million in 2022, then grew by 9.31% to $73.2 million in 2023, then increased by 17.66% to $86.2 million in 2024, then gained by 1.76% to $87.7 million in 2025, then increased by 1.07% to $88.6 million in 2026.
• Business Quant data shows KURA's Shares Outstanding (Diluted Average) at $88.6 million in Q1 2026, $87.7 million in Q4 2025, and $87.6 million in Q3 2025.